Norman Tse, Cfa

Fortitude Biomedicines is a private biotechnology company headquartered in Waltham, Massachusetts, pioneering next-generation immune cell targeting biologics and an antibody–drug conjugate (ADC) platform powered by proprietary molecular glue payloads. By integrating the precision targeting of ADCs with the catalytic power of targeted protein degradation, the company is developing transformative therapies with the potential to expand the therapeutic window of ADCs, overcome resistance mechanisms, and unlock new target space. Leveraging a robust discovery engine and an experienced team of drug hunters, Fortitude is building a differentiated pipeline of biologics and ADCs aimed at delivering meaningful benefits to patients with high unmet medical need. Investor Relations and Media Contact IR@fortitudebio.com

LTZ Therapeutics is an immunotherapy-focused global biotech company pursuing innovative therapies in oncology and autoimmune diseases. Pioneering a novel myeloid engager platform that is guided by reverse translational science, emerging disease biology, and leveraging the power of myeloid cell subsets, particularly macrophages, which offer tremendous potential as an effective therapy to improve the lives of patients with the bold aim to one day eliminate cancer.

Transforming the discovery of oral small molecule therapeutics At QuantX, we leverage the power of computation and modeling to accelerate the discovery of superior medicines for validated targets in immunology and inflammation. Interested in joining our mission to discover breakthrough medicines? Reach out to inquire about vacancies!

The mission of Bluejay Therapeutics is to develop innovative cures for infectious diseases with the first target indication of chronic HDV infection.

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.

AnHeart is now a Nuvation Bio company. For the latest news and updates please visit www.linkedin.com/company/nuvationbio/

Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company with a mission to bring advanced targeted radiopharmaceutical therapies (TRT) to benefit cancer patients in China. Since its inception, Ablaze has secured a partnership with RayzeBio, Inc., an innovative radiopharmaceutical company based in San Diego CA, to gain exclusive development and commercial right to a series of RayzeBio’s products in the greater China region. Leveraging its team’s extensive business experience and network in cross-border product development and deal making, Ablaze strives to become the leader and the partner of choice in the emerging TRT market in China by working with strategic business partners in both China and abroad. For more information, please visit www.ablazepharma.com.

Fountain Therapeutics is building a pipeline of therapeutics to treat age-related diseases by reversing cellular age. The company has combined the expertise of leaders in aging research and computation to build an AI-driven platform that extracts previously hidden cellular features to measure aging with remarkable precision. Fountain is currently screening a large diversity of drug compounds, including small molecules and biologics, to identify novel drugs that specifically reverse the age of cells for the development of therapeutics to treat age-related diseases. Fountain is comprised of an exceptional growing team of scientists, engineers, physicians, drug hunters and developers, and entrepreneurs originating from top academic institutions, research laboratories and biotech companies in the world. The team is united by the common goal of building a new way forward to decouple aging from disease and improve the quality of life for our aging population. Fountain is based in South San Francisco, California. For more information on Fountain, please visit www.fountaintx.com.

Our Mission: To revolutionize the diagnostic, prognostic, and predictive treatment of disease by enabling next generation technologies for non-destructively processing and digitally analyzing tissue in 3D. ClearLight Biotechnologies (formerly ClearLight Diagnostics, LLC) was founded in 2015 by Karl Deisseroth MD, PhD, the inventor of CLARITY, Optogenetics, and STARmap technologies. It is an early stage company focused on developing automated instrumentation and associated reagents to simplify and expedite non-destructive 3D tissue analysis to facilitate preclinical and clinical research applications. The platform will enable an end-to-end solution for 3D analysis of preclinical and clinical models of disease. Imagine, Non-destructive tissue processing and digital spatial image analysis in 3D to facilitate your pre-clinical and clinical research studies. Imagine, A way to illuminate your tissue microenvironment in a 3D volume. Imagine, Automating this process and integrating it into your normal tissue processing work flow. The Problem: Current gold standard techniques are 100 years old and rely on the analysis of 2D thin section FFPE (~5-10 micron). Spatial and morphological analysis of the tissue microenvironment is highly limited. 2D is destructive, slide-based, non-digital, is variable, and highly manual and does not represent the entire biology. The Solution: See more biology in 3D. Bringing CLARITY to the complexity of your 3D histopathology models.

Since its inception in 2013, AccuraGen has pioneered the development of liquid biopsy technology to facilitate more personalized cancer treatment. Our international team of scientists brings together the best of industry with the best of academia. We currently operate from two locations: Menlo Park, California and Shanghai, China.

Based in San Diego and founded in 2013, Omniome is a biotechnology company developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy. Backed by leading life sciences venture investors and a proven management team, Omniome’s vision is to be the most trusted DNA sequencing platform and leader in clinical sequencing. We are a quality-focused, start-up environment where development thrives. Our culture is inspiring, fun and consists of a talented team of individuals who propose innovative ideas keeping collaboration a top priority.

Encodia is developing an innovative Next-Gen digital proteomics platform to enable democratized protein sequencing. Our goal is to make protein sequencing easy and ubiquitous by using a novel reverse-translation technology that turns peptide sequences into DNA. The DNA can be read by an NGS DNA sequencer, providing a path to breakthrough proteomics research at a scale that is not practical or cost-effective using current technologies.

Established in 2010, Vitargent (International) Biotechnology Limited has a vision of "Smarter Testing, Safer Products, Better World"​. We develop bio-testing technologies that include transgenic medaka and zebrafish embryo toxicity testing technologies. In 2013, Vitargent was accredited for the international standard ISO17025 and became the only test centre in Asia that can provide fish embryo toxicity (FET) testing with results officially recognised in more than 100 countries and economies. We are the proud winner of the Grand Prix at the International Exhibition of Inventions of Geneva (2015). 2015 Davos Global Innovation Pioneer, HSBC Young Entrepreneur Award, Second Runner-up of Lee Kuan Yew Global Business Plan Competition, Middle East International Invention Fair Gold Medal, WIPO Gold Medal for Inventors, Korea International Invention Exhibition-Gold Award and Hong Kong Awards for Industries-Technological Achievement Award. Based in Hong Kong with licensed laboratories in Europe and Taiwan, serving top-notch testing organisations, governments, major international cosmetics companies and catering groups around the world. Learn more at www.vitargent.com

Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company’s proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitor’s therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, CNS, autoimmune and musculoskeletal diseases, as well as several rare disorders. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, J&J Innovation - JJDC, SR One, Brace Pharma Capital, Remeditex ventures, Sanofi Ventures and The Longevity Fund.

Fortitude Biomedicines is a private biotechnology company headquartered in Waltham, Massachusetts, pioneering next-generation immune cell targeting biologics and an antibody–drug conjugate (ADC) platform powered by proprietary molecular glue payloads. By integrating the precision targeting of ADCs with the catalytic power of targeted protein degradation, the company is developing transformative therapies with the potential to expand the therapeutic window of ADCs, overcome resistance mechanisms, and unlock new target space. Leveraging a robust discovery engine and an experienced team of drug hunters, Fortitude is building a differentiated pipeline of biologics and ADCs aimed at delivering meaningful benefits to patients with high unmet medical need. Investor Relations and Media Contact IR@fortitudebio.com

LTZ Therapeutics is an immunotherapy-focused global biotech company pursuing innovative therapies in oncology and autoimmune diseases. Pioneering a novel myeloid engager platform that is guided by reverse translational science, emerging disease biology, and leveraging the power of myeloid cell subsets, particularly macrophages, which offer tremendous potential as an effective therapy to improve the lives of patients with the bold aim to one day eliminate cancer.

Transforming the discovery of oral small molecule therapeutics At QuantX, we leverage the power of computation and modeling to accelerate the discovery of superior medicines for validated targets in immunology and inflammation. Interested in joining our mission to discover breakthrough medicines? Reach out to inquire about vacancies!

The mission of Bluejay Therapeutics is to develop innovative cures for infectious diseases with the first target indication of chronic HDV infection.

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.